BioCentury | Apr 6, 2018

Smid-cap smorgasbord

While the biggest milestone of the second quarter came early and turned out to be a disappointment, investors still have plenty to look forward to in immuno-oncology. In addition, specialist investors’ current strategy of overweighting...
BioCentury | Jan 6, 2018

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Nov 30, 2017
Clinical News

FDA accepts NDA for Kitov's KIT-302 to treat OA pain and hypertension

FDA accepted for review an NDA from Kitov Pharmaceuticals Holdings Ltd. (Tel Aviv:KTOV; NASDAQ:KTOV) for celecoxib/amlodipine besylate (KIT-302) to treat pain associated with osteoarthritis and hypertension simultaneously. The PDUFA date is May 31. The candidate...
BC Week In Review | Mar 17, 2017
Company News

Kitov, Kuhnil deal

Kitov granted Kuhnil exclusive South Korean rights to develop and commercialize KIT-302 . Kitov is eligible for undisclosed regulatory milestones and double-digit royalties. Kuhnil will be responsible for obtaining regulatory approval in South Korea and expects...
BC Week In Review | Jul 25, 2016
Clinical News

Celecoxib/amlodipine besylate: Additional Phase III data

Additional data from a double-blind, placebo-controlled, U.K. Phase III trial in 152 patients with hypertension showed that once-daily oral 200 mg celecoxib/10 mg amlodipine besylate for 2 weeks reduced serum creatinine levels by 3.22 umol/L...
BioCentury | Jul 11, 2016

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which...
BioCentury | Jan 11, 2016

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Dec 21, 2015
Clinical News

Celecoxib/amlodipine besylate: Phase III data

A double-blind, placebo-controlled, U.K. Phase IlI trial in 152 patients with hypertension showed that once-daily oral 200 mg celecoxib/10 mg amlodipine besylate for 2 weeks met the primary endpoint of achieving a reduction in daytime...
BC Week In Review | Nov 9, 2015
Clinical News

Celecoxib/amlodipine besylate: Completed Phase III enrollment

Kitov completed enrollment of 150 patients in a double-blind, international Phase III trial comparing oral 200 mg celecoxib/10 mg amlodipine besylate once daily for 2 weeks vs. each of its components or placebo. The company...
BioCentury | Jul 13, 2015

Big news

The performance of big cap biotechs has lagged that of companies one tier down, but the second half includes a host of milestones that could put the bellwethers on a steeper upward trajectory. Buysiders largely...
Items per page:
1 - 10 of 10